Rehabilitation in Parkinson's disease: assessing the outcome using objective metabolic measurements.

Frazzitta G, Maestri R, Bertotti G, Uccellini D, Bazzini G, Abelli P, Aquilani R.

Mov Disord. 2010 Apr 15;25(5):609-14. doi: 10.1002/mds.22871.

Major life events and risk of Parkinson's disease.

Rod NH, Hansen J, Schernhammer E, Ritz B.

Mov Disord. 2010 Aug 15;25(11):1639-45. doi: 10.1002/mds.22850.

Reprogramming guided by the fused images of MRI and CT in subthalamic nucleus stimulation in Parkinson disease.

Lee JY, Jeon BS, Paek SH, Lim YH, Kim MR, Kim C.

Clin Neurol Neurosurg. 2010 Jan;112(1):47-53. doi: 10.1016/j.clineuro.2009.10.008.

Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.

Sala G, Brighina L, Saracchi E, Fermi S, Riva C, Carrozza V, Pirovano M, Ferrarese C.

J Neural Transm (Vienna). 2010 Sep;117(9):1093-8. doi: 10.1007/s00702-010-0446-z.

Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.

Tang CC, Poston KL, Dhawan V, Eidelberg D.

J Neurosci. 2010 Jan 20;30(3):1049-56. doi: 10.1523/JNEUROSCI.4188-09.2010.

Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases.

Nakamura T, Lipton SA.

Apoptosis. 2010 Nov;15(11):1354-63. doi: 10.1007/s10495-010-0476-x. Review.

The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease: serial transcranial Doppler studies.

Yong SW, Lee KY, Lee PH.

Parkinsonism Relat Disord. 2010 Mar;16(3):225-7. doi: 10.1016/j.parkreldis.2009.09.003.

Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.

Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Kim HK, Ryu JS, Kim GS, Lee MC, Chung SJ, Koh JM.

Calcif Tissue Int. 2010 Feb;86(2):132-41. doi: 10.1007/s00223-009-9327-6.

The effect of Parkinson's disease on the dynamics of on-line and proactive cognitive control during action selection.

Wylie SA, Ridderinkhof KR, Bashore TR, van den Wildenberg WP.

J Cogn Neurosci. 2010 Sep;22(9):2058-73. doi: 10.1162/jocn.2009.21326.

Lower extremity isokinetic muscle strength in patients with Parkinson's disease.

Durmus B, Baysal O, Altinayar S, Altay Z, Ersoy Y, Ozcan C.

J Clin Neurosci. 2010 Jul;17(7):893-6. doi: 10.1016/j.jocn.2009.11.014.

Analysis of exon dosage using MLPA in South African Parkinson's disease patients.

Keyser RJ, Lombard D, Veikondis R, Carr J, Bardien S.

Neurogenetics. 2010 Jul;11(3):305-12. doi: 10.1007/s10048-009-0229-6.

Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.

van Laar T, Postma AG, Drent M.

Parkinsonism Relat Disord. 2010 Jan;16(1):71-2. doi: 10.1016/j.parkreldis.2009.05.006. No abstract available.

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.

Schulz-Schaeffer WJ.

Acta Neuropathol. 2010 Aug;120(2):131-43. doi: 10.1007/s00401-010-0711-0. Review.

Transdermal rotigotine for the perioperative management of Parkinson's disease.

Wüllner U, Kassubek J, Odin P, Schwarz M, Naumann M, Häck HJ, Boroojerdi B, Reichmann H; NEUPOS Study Group..

J Neural Transm (Vienna). 2010 Jul;117(7):855-9. doi: 10.1007/s00702-010-0425-4.

Preventing Parkinson's pathology.

DeSantis ME, Dersh D.

Dis Model Mech. 2010 Jul-Aug;3(7-8):399-400. doi: 10.1242/dmm.005678. No abstract available.